BC Extra | Jul 19, 2019
Company News

July 18 Company Quick Takes: Mallinckrodt, Silence in RNAi deal; plus Pear, Blueprint and more

Mallinckrodt licenses RNAi candidate from Silence  Mallinckrodt plc (NYSE:MNK) obtained an exclusive, worldwide license to C3-targeted RNAi therapy SLN500 from Silence Therapeutics plc (LSE:SLN), plus options to license up to two additional complement-targeted preclinical candidates....
BioCentury | Dec 8, 2018
Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
BC Week In Review | Feb 2, 2018
Clinical News

MacroGenics reports Phase I data of flotetuzumab for AML

MacroGenics Inc. (NASDAQ:MGNX) reported preliminary data from 8 evaluable patients with acute myelogenous leukemia (AML) in a dose-expansion cohort of a Phase I trial showing that 500 ng/kg/day IV flotetuzumab (CD3xCD123 DART molecule, MGD006, S80880)...
BC Week In Review | Oct 27, 2017
Company News

Incyte gains rights to Macrogenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012 . MacroGenics retains rights to develop combinations that include the mAb and its pipeline assets. MacroGenics is to...
BC Extra | Oct 25, 2017
Company News

Incyte gains rights to MacroGenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012 . MacroGenics, which retains rights to develop combinations that include the mAb and its pipeline assets, climbed $2.81...
BC Innovations | Jun 25, 2015
Product R&D

Cellectis' UCART-ography

A year after Pfizer Inc. threw its weight behind Cellectis S.A. 's chimeric antigen receptor (CAR) T cell platform, the biotech has signed a three-year partnership with Weill Cornell Medical College to test whether its...
BioCentury | Sep 22, 2014
Product Development

Glenmark's new cancer BEAT

While bispecific antibodies have been around for two decades, their success in cancer has been stymied by poor in vivo properties and complex manufacturing processes. Indian biotech Glenmark Pharmaceuticals Ltd. is making a play in...
BC Week In Review | Jun 23, 2014
Clinical News

CD3xCD123 DART molecule: Phase I started

MacroGenics began an open-label, dose-escalation, U.S. Phase I trial to evaluate MGD006 in up to 58 patients with relapsed or refractory AML. Once the maximum tolerated dose is established, the selected dose cohort will be...
BC Week In Review | Feb 10, 2014
Company News

MacroGenics, Servier deal

MacroGenics said Servier exercised its option to acquire rights to develop and commercialize MGD006 outside of North America, Japan, South Korea and India. MacroGenics, which will retain rights in those regions, will receive a $20...
BC Week In Review | Jan 20, 2014
Clinical News

MacroGenics preclinical data

In mice infused with primary AML xenografts, MGD006 led to a >97% reduction of AML blasts from the peripheral blood and a 40-77.8% reduction from the spleen and bone marrow at 6 weeks post-infusion. Data...
Items per page:
1 - 10 of 11